Clinical Study
Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection
| Variable | | Mean |
| Reasons for initiation to RLAI* (%) | | | Adverse event: weight gain | 177 | 3 (1.7%) | Adverse event: extrapyramidal symptoms | 177 | 14 (7.9%) | Adverse event: other | 177 | 11 (6.2%) | Lack of efficacy | 177 | 61 (34.5%) | Relapse | 177 | 47 (26.6%) | Patient choice | 177 | 26 (14.7%) | Noncompliance | 177 | 112 (63.3%) | Unknown | 177 | 0 | Duration of RLAI use (days) | 177 | 485.5 (SD 287.4) range 0–936 | RLAI persistence (proportion of patients known to continue therapy during) | | | at least 6 months | 175† | 134 (76.6%) | at least 12 months | 172† | 122 (70.9%) | at least 18 months | 128† | 87 (68.0%) | at least 24 months | 68† | 45 (66.2%) | Reasons for stopping RLAI* (%) | | | Adverse event: weight gain | 66 | 2 (3.0%) | Adverse event: extrapyramidal | 66 | 3 (4.5%) | Adverse event: other | 66 | 10 (15.2%) | Lack of efficacy | 66 | 23 (34.8%) | Relapse | 66 | 2 (3.0%) | Patient choice | 66 | 22 (33.3%) | Noncompliance | 66 | 23 (34.8%) | Unknown | 66 | 0 |
|
|
*Multiple answers were allowed. †Reduced sample size reflects follow-up durations.
|